Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial assessing Apta1

Trial Profile

A phase II trial assessing Apta1

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apta 1 (Primary)
  • Indications Sepsis
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 13 Mar 2025 According to Aptahem media release,the company announced a synopsis for the upcoming clinical phase 2 study of the drug candidate Apta-1.
  • 18 Apr 2024 According to Aptahem media release, the company has decided to revise its clinical development strategy by performing a Proof-of-Concept (PoC) study.The final study design is now under evaluation.
  • 04 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top